The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter

被引：37

作者：

Lowe, John A., III ^{[1
]}

Hou, Xinjun ^{[1
]}

Schmidt, Christopher ^{[1
]}

Tingley, F. David, III ^{[1
]}

McHardy, Stan ^{[1
]}

Kalman, Monica ^{[1
]}

DeNinno, Shari ^{[1
]}

Sanner, Mark ^{[1
]}

Ward, Karen ^{[1
]}

Lebel, Lorraine ^{[1
]}

Tunucci, Don ^{[1
]}

Valentine, James ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, Groton, CT 06340 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2009年 / 19卷 / 11期

关键词：

Glycine; Transporter; Inhibitor; 3.1.0]-Azabicyclic; Schizophrenia; NMDA;

D O I：

10.1016/j.bmcl.2009.04.035

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The type 1 glycine transporter plays an important in regulating homeostatic glycine levels in the brain that are relevant to the activation of the NMDA receptor by the excitatory neurotransmitter glutamate. We describe herein the structure-activity relationships (SAR) of a structurally novel class of GlyT1 inhibitors following on a lead derived from high throughput screening, which shows good selectivity for GlyT1 and potent activity in elevating CSF levels of glycine. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：2974 / 2976

页数：3

共 50 条

[21] Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models
Socala, Katarzyna
Nieoczym, Dorota
Rundfeldt, Chris
Wlaz, Piotr
PHARMACOLOGICAL REPORTS, 2010, 62 (02) : 392 - 397
[22] Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models
Katarzyna Socała
Dorota Nieoczym
Chris Rundfeldt
Piotr Wlaź
Pharmacological Reports, 2010, 62 : 392 - 397
[23] Preclinical Reproductive and Developmental Toxicity Profile of a Glycine Transporter Type 1 (Glyt1) Inhibitor
Barrow, Paul
Parrott, Neil
Alberati, Daniela
Paehler, Axel
Koerner, Annette
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2016, 107 (03) : 148 - 156
[24] PKCβ-dependent phosphorylation of the glycine transporter 1
Vargas-Medrano, Javier
Castrejon-Tellez, Vicente
Plenge, Fernando
Ramirez, Ivan
Miranda, Manuel
NEUROCHEMISTRY INTERNATIONAL, 2011, 59 (08) : 1123 - 1132
[25] An Overview of Glycine Transporter Subtype 1 Inhibitors Under Preclinical and Clinical Evaluation for the Treatment of Alcohol Abuse
Harhai, Marcell
Harsing Jr, Laszlo G.
CURRENT PSYCHIATRY RESEARCH AND REVIEWS, 2022, 18 (01) : 17 - 35
[26] Glycine transporter-1 inhibitors: a patent review (2011-2016)
Cioffi, Christopher L.
EXPERT OPINION ON THERAPEUTIC PATENTS, 2018, 28 (03) : 197 - 210
[27] Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia
Hashimoto, Kenji
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (02) : 112 - 120
[28] Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders
Cioffi, Christopher L.
Guzzo, Peter R.
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (29) : 3404 - 3437
[29] Discovery of novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling
Yang, Huaiyu
Dou, Wei
Lou, Jing
Leng, Ying
Shen, Jianhua
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (04) : 1340 - 1345
[30] A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies
Zeng, Zhizhen
O'Brien, Julie A.
Lemaire, Wei
O'Malley, Stacey S.
Miller, Patricia J.
Zhao, Zhijian
Wallace, Michael A.
Raab, Conrad
Lindsley, Craig W.
Sur, Cyrille
Williams, David L., Jr.
NUCLEAR MEDICINE AND BIOLOGY, 2008, 35 (03) : 315 - 325

← 1 2 3 4 5 →